Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00516893 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00516893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00516893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
December 31, 2007
Enrollment
113 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis